Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

142P - Correlation between histological pattern and hotspots EGFR mutations in Moroccan lung adenocarcinoma

Date

17 Sep 2020

Session

E-Poster Display

Topics

Targeted Therapy

Tumour Site

Thoracic Malignancies

Presenters

Sara BOUKANSA

Citation

Annals of Oncology (2020) 31 (suppl_4): S274-S302. 10.1016/annonc/annonc266

Authors

S. BOUKANSA1, S. Bardai2, L. Bouguenouch3, Z. Benbrahim4, N. Mellas4, M. Serraj5, Y. Ouadnouni6, M. Smahi6, B. Alami7, H. EL FATEMI8

Author affiliations

  • 1 Medical Centre Of Biomedical And Translational Research, Faculty Of Medicine And Pharmacy Fez, CHU - University Hospital of Hassan II, 30020 - Fez/MA
  • 2 Anatomy And Cyto-pathologycal Department, CHU - University Hospital of Hassan II, 3000 - Fez/MA
  • 3 Oncogenetics And Medical Genetics Department, CHU - University Hospital of Hassan II, 3000 - FEZ/MA
  • 4 Department Of Oncology, CHU - University Hospital of Hassan II, 30000 - Fez/MA
  • 5 Department Of Pneumology, CHU - University Hospital of Hassan II, 3000 - Fez/MA
  • 6 Department Of Thoracic Surgery, CHU - University Hospital of Hassan II, 3000 - Fez/MA
  • 7 Department Of Radiology, CHU - University Hospital of Hassan II, 3000 - Fez/MA
  • 8 Anatomy And Cyto-pathologycal Department, CHU - University Hospital of Hassan II, 30000 - Fez/MA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 142P

Background

lung cancer is considered as the most common cause of cancer death in world. Adenocarcinoma (ADK) is currently the most common histological subtype of this disease, accounting for 85% of all lung cancer cases. The majorities of patients with lung adenocarcinoma have advanced disease and are not candidates for local therapy. The epidermal growth factor receptor (EGFR) represents a potential molecular target for personalized therapy with (ITKs) in Lung ADC. The aim of this study is to define the association of EGFR mutations with predominant histological pattern lung adenocarcinoma in Moroccan population.

Methods

135 FFPE tumours diagnosed with lung adenocarcinoma were included between November 2017 and May 2020. Histological subclassification was registered by a pathologist. Automatic direct sequencing was performed for samples with Tumor cells >30% ; The therascreen EGFR RGQ Kit was used for specimen with tumor cells <30%.

Results

27 lung adenocarcinoma were EGFR mutated, more frequently found among women (30%) than in men (15,7%) and non-smokers (non-smokers vs active smokers, 35.7% against 8%). Regarding histological subtypes, the most frequent one was acinar (40%), followed by solid (35,25%), papillary (14.28%) and lepidic (5,71%). EGFR mutation tend to be common in papillary predominant (40%), followed by acinar predominant (33,33%), lepidic predominant (16,6%) and solid predominant (8,1%). EGFR exon mutation distribution was similar to that generally reported in the literature. The main types were in-frame deletions in exon 19 (55,55%), followed by the missenses substitutions in exon 21 (37,03%), exon 20 mutations (11,11%) and exon 18 (3,7%). Exon 19 were significantly more frequent in tumors with papillary pattern (p=0,048), while exon 21 substitutions tend to be associated with acinar predominant pattern (p=0,017). Thyroid transcription factor-1 expression wasn’t seen in two EGFR-mutant-positive tumors. A significant association was revealed between EGFR mutations and female gender (p < 0,05), non-smokers (p <0.001), acinary predominant pattern. (p = 0.03).

Conclusions

In our population, the female gender, non smoking status and acinar predominant pattern may predict the presence of EGFR mutation in lung adenocarcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hinde El Fatemi.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.